1.1 Initial claudication distance (ICD) |
6 |
1722 |
Mean Difference (IV, Fixed, 95% CI) |
26.49 [18.93, 34.05] |
1.1.1 Cilostazol 50 mg twice daily |
2 |
400 |
Mean Difference (IV, Fixed, 95% CI) |
19.50 [6.80, 32.21] |
1.1.2 Cilostazol 100 mg twice daily |
6 |
1236 |
Mean Difference (IV, Fixed, 95% CI) |
32.19 [22.20, 42.18] |
1.1.3 Cilostazol 150 mg twice daily |
1 |
86 |
Mean Difference (IV, Fixed, 95% CI) |
15.70 [‐12.20, 43.60] |
1.2 Absolute claudication distance (ACD) |
8 |
2360 |
Mean Difference (IV, Random, 95% CI) |
39.57 [21.80, 57.33] |
1.2.1 Cilostazol 50 mg twice daily |
2 |
400 |
Mean Difference (IV, Random, 95% CI) |
30.84 [8.81, 52.86] |
1.2.2 Cilostazol 100 mg twice daily |
8 |
1874 |
Mean Difference (IV, Random, 95% CI) |
42.32 [18.12, 66.51] |
1.2.3 Cilostazol 150 mg twice daily |
1 |
86 |
Mean Difference (IV, Random, 95% CI) |
51.80 [‐10.59, 114.19] |
1.3 Arterial revascularisation |
1 |
516 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.16 [0.01, 4.07] |
1.3.1 Cilostazol 50 mg twice daily |
1 |
256 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.16 [0.01, 4.07] |
1.3.2 Cilostazol 100 mg twice daily |
1 |
260 |
Odds Ratio (M‐H, Fixed, 95% CI) |
Not estimable |
1.4 Amputation |
1 |
516 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.16 [0.01, 4.07] |
1.4.1 Cilostazol 50 mg twice daily |
1 |
256 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.16 [0.01, 4.07] |
1.4.2 Cilostazol 100 mg twice daily |
1 |
260 |
Odds Ratio (M‐H, Fixed, 95% CI) |
Not estimable |
1.5 Adverse event related to study medication ‐ headache |
8 |
2584 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.83 [2.26, 3.55] |
1.5.1 Cilostazol 50 mg twice daily |
2 |
453 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.02 [1.19, 3.43] |
1.5.2 Cilostazol 100 mg twice daily |
8 |
2131 |
Odds Ratio (M‐H, Fixed, 95% CI) |
3.05 [2.38, 3.92] |
1.6 Adverse event related to study medication ‐ diarrhoea |
7 |
2503 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.73 [2.02, 3.70] |
1.6.1 Cilostazol 50 mg twice daily |
2 |
453 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.02 [0.91, 4.52] |
1.6.2 Cilostazol 100 mg twice daily |
7 |
2050 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.88 [2.07, 3.99] |
1.7 Adverse event related to study medication ‐ abnormal stools |
5 |
1804 |
Odds Ratio (M‐H, Fixed, 95% CI) |
3.63 [2.45, 5.38] |
1.7.1 Cilostazol 50 mg twice daily |
2 |
453 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.48 [1.08, 5.71] |
1.7.2 Cilostazol 100 mg twice daily |
5 |
1351 |
Odds Ratio (M‐H, Fixed, 95% CI) |
4.04 [2.59, 6.31] |
1.8 Adverse event related to study medication ‐ dizziness |
4 |
1120 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.42 [1.43, 4.08] |
1.8.1 Cilostazol 50 mg twice daily |
1 |
256 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.95 [0.63, 6.06] |
1.8.2 Cilostazol 100 mg twice daily |
4 |
864 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.57 [1.42, 4.63] |
1.9 Adverse event related to study medication ‐ pain |
4 |
1572 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.71, 1.30] |
1.9.1 Cilostazol 50 mg twice daily |
1 |
197 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.53 [0.67, 3.48] |
1.9.2 Cilostazol 100 mg twice daily |
4 |
1375 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.88 [0.64, 1.23] |
1.10 Adverse event related to study medication ‐ palpitations |
4 |
1681 |
Odds Ratio (M‐H, Fixed, 95% CI) |
7.16 [3.95, 12.98] |
1.10.1 Cilostazol 50 mg twice daily |
1 |
256 |
Odds Ratio (M‐H, Fixed, 95% CI) |
8.89 [0.51, 155.87] |
1.10.2 Cilostazol 100 mg twice daily |
4 |
1425 |
Odds Ratio (M‐H, Fixed, 95% CI) |
7.06 [3.85, 12.96] |
1.11 Cardiovascular event |
2 |
692 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.50 [0.51, 4.47] |
1.11.1 Cilostazol 50 mg twice daily |
1 |
256 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.51 [0.30, 7.64] |
1.11.2 Cilostazol 100 mg twice daily |
2 |
436 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.50 [0.35, 6.52] |
1.12 All‐cause mortality |
8 |
2642 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.41, 2.30] |
1.12.1 Cilostazol 50 mg twice daily |
2 |
453 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.49 [0.03, 8.00] |
1.12.2 Cilostazol 100 mg twice daily |
8 |
2189 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.04 [0.42, 2.59] |
1.13 Ankle brachial index (ABI) |
3 |
859 |
Mean Difference (IV, Random, 95% CI) |
0.06 [0.04, 0.08] |
1.13.1 Cilostazol 100 mg twice daily |
3 |
859 |
Mean Difference (IV, Random, 95% CI) |
0.06 [0.04, 0.08] |
1.14 Initial claudication distance (ICD) sensitivity analysis |
5 |
1543 |
Mean Difference (IV, Fixed, 95% CI) |
29.52 [21.26, 37.78] |
1.14.1 Cilostazol 50 mg twice daily |
2 |
400 |
Mean Difference (IV, Fixed, 95% CI) |
19.50 [6.80, 32.21] |
1.14.2 Cilostazol 100 mg twice daily |
5 |
1143 |
Mean Difference (IV, Fixed, 95% CI) |
36.86 [25.98, 47.74] |
1.15 Absolute claudication distance (ACD) sensitivity analysis |
6 |
1732 |
Mean Difference (IV, Random, 95% CI) |
48.44 [34.49, 62.39] |
1.15.1 Cilostazol 50 mg twice daily |
2 |
400 |
Mean Difference (IV, Random, 95% CI) |
30.84 [8.81, 52.86] |
1.15.2 Cilostazol 100 mg twice daily |
6 |
1332 |
Mean Difference (IV, Random, 95% CI) |
56.30 [40.37, 72.23] |
1.16 Adverse event related to study medication ‐ headache, sensitivity analysis |
7 |
2061 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.83 [2.21, 3.61] |
1.16.1 Cilostazol 50 mg twice daily |
2 |
453 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.02 [1.19, 3.43] |
1.16.2 Cilostazol 100 mg twice daily |
7 |
1608 |
Odds Ratio (M‐H, Fixed, 95% CI) |
3.10 [2.35, 4.09] |
1.17 Adverse event related to study medication ‐ diarrhoea, sensitivity analysis |
6 |
1980 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.91 [2.05, 4.12] |
1.17.1 Cilostazol 50 mg twice daily |
2 |
453 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.02 [0.91, 4.52] |
1.17.2 Cilostazol 100 mg twice daily |
6 |
1527 |
Odds Ratio (M‐H, Fixed, 95% CI) |
3.16 [2.15, 4.67] |
1.18 Adverse event related to study medication ‐ pain, sensitivity analysis |
3 |
1049 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.07 [0.75, 1.54] |
1.18.1 Cilostazol 50 mg twice daily |
1 |
197 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.53 [0.67, 3.48] |
1.18.2 Cilostazol 100 mg twice daily |
3 |
852 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.98 [0.66, 1.47] |
1.19 Adverse event related to study medication ‐ palpitations, sensitivity analysis |
3 |
1158 |
Odds Ratio (M‐H, Fixed, 95% CI) |
12.80 [5.06, 32.36] |
1.19.1 Cilostazol 50 mg twice daily |
1 |
256 |
Odds Ratio (M‐H, Fixed, 95% CI) |
8.89 [0.51, 155.87] |
1.19.2 Cilostazol 100 mg twice daily |
3 |
902 |
Odds Ratio (M‐H, Fixed, 95% CI) |
13.42 [5.05, 35.68] |
1.20 All‐cause mortality sensitivity analysis |
7 |
2119 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.21 [0.47, 3.13] |
1.20.1 Cilostazol 50 mg twice daily |
2 |
453 |
Odds Ratio (M‐H, Fixed, 95% CI) |
0.49 [0.03, 8.00] |
1.20.2 Cilostazol 100 mg twice daily |
7 |
1666 |
Odds Ratio (M‐H, Fixed, 95% CI) |
1.36 [0.49, 3.75] |